Substance Use and Medication Safety in Pregnancy

Substance use and medication safety in pregnancy covers two linked concerns: exposure to substances such as alcohol, tobacco, opioids, and other drugs of use, and the safety of prescribed and over-the-counter medications taken during pregnancy. Both raise the question of whether an agent crossing the placenta can disrupt fetal development (teratogenesis) or cause neonatal effects, and both require weighing fetal exposure against the maternal benefit of treatment.

Definition

Substance use and medication safety in pregnancy refers to the assessment of how drugs of use and therapeutic medications taken during pregnancy may affect the embryo, fetus, or neonate, and to the principle of balancing fetal exposure against the maternal need for treatment.

Scope

The topic covers the core concepts of teratology, the placental transfer of drugs and substances, the idea of a risk-benefit balance when treating maternal disease, and recognised perinatal effects such as neonatal abstinence syndrome. It is a reference entry on these concepts and does not provide drug-specific safety ratings, dosing, or treatment recommendations.

Core questions

• What determines whether a substance or medication crossing the placenta harms the developing fetus?
• Why does the timing of exposure relative to development affect the type of harm?
• How is the risk of fetal exposure weighed against the benefit of treating maternal disease?
• What are recognised neonatal effects of prenatal substance exposure, such as withdrawal?

Key concepts

• Teratology and teratogenesis
• Placental drug transfer
• Critical periods of development
• Dose and timing of exposure
• Risk-benefit balance of maternal treatment
• Fetal alcohol spectrum disorders
• Neonatal abstinence syndrome / neonatal opioid withdrawal

Mechanisms

Most drugs and many substances of use cross the placenta to some degree, so the fetus can be exposed whenever the pregnant person is. Whether exposure causes harm depends on the agent's intrinsic toxicity, the dose, and especially the timing relative to development: exposure during organogenesis in the first trimester can cause structural malformation, while later exposure more often affects growth, function, or the neonate. Some exposures produce neonatal effects after birth — for example, prenatal opioid exposure can lead to neonatal abstinence syndrome (neonatal opioid withdrawal). Because untreated maternal illness can itself harm the pregnancy, medication decisions involve balancing the potential fetal risk of a drug against the maternal and fetal benefit of treating the condition. Knowledge of any given medication's risk is often incomplete, since pregnant people are typically excluded from drug trials.

Clinical relevance

These concepts underpin pre-conception and antenatal counselling about medications and substance use, the interpretation of teratology information resources, and recognition of neonatal effects of exposure. This entry is reference orientation to teratology and perinatal exposure; it makes no statement about the safety of any specific drug and provides no dosing or treatment advice.

Epidemiology

Alcohol, tobacco, and opioid exposure in pregnancy are recurrently studied contributors to adverse perinatal outcomes, and the rise in opioid use has been accompanied by increasing rates of neonatal abstinence syndrome reported in the obstetric and neonatal literature. Most pregnant people take at least one medication during pregnancy, yet pregnancy-specific safety evidence is frequently limited.

History

Modern teratology was galvanised by the thalidomide tragedy of the early 1960s, which demonstrated that a medication could cause severe malformation and prompted systems for evaluating drug safety in pregnancy. Subsequent decades shifted from simplistic letter-category labels toward narrative, evidence-based risk communication, as reflected in contemporary teratology reviews.

Seminal works

• adam-2011
• mcqueen-2016

Frequently asked questions

Why does the timing of an exposure in pregnancy matter?

Different structures develop at different times, so the gestational age at exposure influences the effect: exposure during first-trimester organ formation can cause structural malformation, whereas later exposure more often affects growth, function, or the newborn.

What is neonatal abstinence syndrome?

It is a constellation of withdrawal signs in a newborn following prenatal exposure to certain substances, most often opioids; it reflects the cessation of fetal exposure at birth rather than a malformation of development.